Minimising non-human primate use in drug development

In the realm of DNA sequencing, technology developers contribute to advancement in important ways, by building increasingly fast-moving tools that untangle the intricacies of the human genome, and by constructing analytics platforms to wade through the resulting mountains of genetic data.

Various neurodegenerative processes result in the development of diseases like Alzheimer’s (AD), Parkinson’s (PD), amyotrophic lateral sclerosis (ALS), and, arguably, multiple sclerosis (MS). Despite years of research, drug discovery initiatives, and promising clinical trials, these diseases remain incurable. But recent studies have suggested common mechanisms underlying these pathologies. Atypical protein assembly resulting in plaque formation is a common pathological finding in both AD and PD, while neuronal death is a primary (ALS) or secondary (MS) hallmark of the disease. For a detailed look at the mechanisms that drive an array of neurodegenerative diseases, The Scientist is bringing together a panel of experts to share their research, discuss current therapeutic approaches, and offer their insights. Come engage with our panel and get the answers you seek.

The ability to link disparate datasets with de-identified or anonymized patient data has existed for decades but has been unrealistic to apply at scale.

With the increase and complexity of the global supply chain, both the pharmaceutical cold chain and temperature-controlled shipping for the food and beverage industry have seen substantial growth over the last few years. It is no coincidence that the food industry is now beginning to look to the pharmaceutical supply chain for guidance on best practices, as the need for stricter standardization and controls has emerged.